Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.20.2
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2019
Mar. 31, 2015
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
May 31, 2016
Neupharma [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments   $ 40,000,000.0          
Neupharma [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments   40,000,000.0          
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments   22,500,000          
Dana-Farber [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maintenance fee   50,000          
Dana-Farber [Member] | First Commercial Sale Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     $ 27,600,000   $ 27,600,000    
Maximum potential milestone payments   21,500,000          
Dana-Farber [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     60,000,000.0   60,000,000.0    
Maximum potential milestone payments   60,000,000.0          
Dana-Farber [Member] | Commercial Sales In Specified Territories [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     21,500,000   21,500,000    
Jubilant Biosys Ltd [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone revenue recognized     $ 21,000 $ 13,000 $ 67,000 $ 37,000  
Research and development cost     50.00%   50.00%    
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments             $ 89,000,000.0
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments             59,500,000
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     $ 61,700,000   $ 61,700,000    
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     89,000,000.0   89,000,000.0    
Maximum potential milestone payments             $ 89,000,000.0
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     87,200,000   87,200,000    
Adimab LLC [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments     7,100,000   7,100,000    
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments     4,800,000   4,800,000    
Collaboration Agreement With TGTX [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment of upfront licensing fees $ 1,000,000.0            
Revenue recognition milestone revenue recognized     7,000 $ 267,000 1,000,000.0 $ 1,600,000  
Proceeds from upfront fees   $ 500,000          
Collaboration Agreement With TGTX [Member] | PD-L1 [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum potential milestone payments     925,000   925,000    
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     7,000,000.0   7,000,000.0    
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     14,500,000   14,500,000    
Collaboration Agreement With TGTX [Member] | Five Regulatory Approvals And First Commercial Sales [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     19,200,000   19,200,000    
Collaboration Agreement With TGTX [Member] | Clinical Development and Regulatory Milestones [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     8,400,000   8,400,000    
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue recognition milestone payments     $ 25,500,000   $ 25,500,000